7,688.62

+119.70

+1.58%

53,356.12

+1,569.40

+3.03%

25,736.51

+364.50

+1.44%

2,856.95

+44.50

+1.58%

4.8940

-0.0580

-1.17%

16.61

-4.22

-20.26%

4,073.80

+0.80

+0.02%

80,547.76

+3,211.01

+4.15%

Crude Oil Dec 26

88.19

+0.07

+0.08%

US Private Equity

10,855.23

+18.94

+0.17%

KSE - Delayed Quote KRW

GC Biopharma Corp. (006280.KS)

138,600.00 +2,300.00 (+1.69%)

At close: 3:30:30 PM GMT+9

GC Biopharma to Present Expanded IVIG Aggregation Analysis and Additional Phase 3 ALYGLO® Safety Analysis at IgNS 2026

Business Wire 22d ago

006280.KS
+1.69%
Osivax and GC Biopharma Enter Strategic Collaboration to Develop a Next-Generation Influenza Vaccine Combining OVX836 and GC FLU

GlobeNewswire 2mo ago

006280.KS
+1.69%
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease

PR Newswire 6d ago

BMRN

006280.KS
+1.69%
128940.KS
Osivax Reports Phase 2b Results for OVX836 and Advances Combination Strategy for Next-Generation Seasonal Influenza Vaccines

GlobeNewswire 20d ago

006280.KS
+1.69%
GC Biopharma's Hunter Syndrome Treatment 'Hunterase' Receives Drug Approval in India and Taiwan

PR Newswire 2mo ago

006280.KS
+1.69%
Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking

Stocktwits 4d ago

BMRN

006280.KS
+1.69%
128940.KS

Mobilize your Website

View Site in Mobile | Classic

Share by: